Marianne et al reported 1 000 high‐risk breast cancer patients received postmastectomy radiotherapy (PMRT) and demonstrated that HoR, HER2 status, and the constructed subtypes may be predictive of locoregional recurrence and survival. This evidence concerns the gene ERBB2 and breast cancer.